Crestor
In brief
- In our pharmacy you can buy crestor without a prescription, with discreet packaging and delivery across Australia.
- Crestor (rosuvastatin) is used to lower LDL cholesterol and reduce cardiovascular risk; it works as an HMG‑CoA reductase inhibitor (a statin) reducing hepatic cholesterol synthesis and increasing LDL receptor uptake.
- Usual dosage: adults typically start 10–20 mg once daily (dose range 5–40 mg daily; max 40 mg); lower starting doses (often 5 mg) are recommended for people of Asian descent, those with renal impairment or the elderly; paediatric heterozygous familial hypercholesterolaemia dosing is usually 5–10 mg (ages 8–17).
- Form of administration: oral tablets (commonly 5 mg, 10 mg, 20 mg, 40 mg) and sprinkle capsules for patients with swallowing difficulties; taken once daily.
- Onset time: reductions in LDL cholesterol can be seen within 1–2 weeks, with substantial effect by 2–4 weeks and near‑maximal LDL lowering by about 4–6 weeks.
- Duration of action: rosuvastatin has a half‑life of roughly 19 hours and provides LDL‑lowering effects over 24 hours, so it is effective with once‑daily dosing and requires ongoing therapy for persistent benefit.
- Alcohol warning: avoid excessive alcohol intake and do not drink heavily while taking crestor, as alcohol increases the risk of liver injury; crestor is contraindicated in active liver disease.
- The most common side effect is muscle pain (myalgia); other common adverse effects include headache, nausea or abdominal pain, arthralgia and elevations in liver enzymes—seek medical advice for unexplained severe muscle pain, weakness or dark urine.
- Would you like to try crestor without a prescription?
Basic Crestor Information
- INN (International Nonproprietary Name): Rosuvastatin.
- Brand Names Available In Australia: Crestor (originator), Ezallor Sprinkle (sprinkle capsules available internationally), and multiple generics supplied by manufacturers such as Teva, Sandoz, Mylan and Sun Pharma.
- ATC Code: C10AA07 (Cardiovascular system; lipid‑modifying agents; HMG‑CoA reductase inhibitors; rosuvastatin).
- Forms & Dosages: Oral tablets 5 mg, 10 mg, 20 mg and 40 mg; oral sprinkle capsules available in some markets for swallowing difficulty.
- Manufacturers In Australia: AstraZeneca is the originator and global supplier; a range of generic manufacturers supply rosuvastatin in global markets and may appear on Australian supply lists.
- Registration Status In Australia: Rosuvastatin is registered by major regulatory authorities and is listed under brand and generic names in multiple jurisdictions; check the TGA/ARTG for exact Australian entries.
- OTC / Rx Classification: Prescription medication (Rx) in all international markets, including Australia.
Critical Warnings, Restrictions And Patient Protection (Australia)
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
Who Should Be Screened Immediately Before Supply?
- Pregnancy or lactation status confirmed or ruled out.
- Active liver disease or a history of unexplained persistent transaminase elevations.
- Significant renal impairment or recent creatinine estimates available.
- Previous statin myopathy or unexplained muscle pain with prior statin use.
- Excessive alcohol use or alcohol use disorder.
- Concomitant use of interacting medicines such as cyclosporine or gemfibrozil.
- Asian ancestry — consider lower starting dose due to higher plasma concentrations.
Absolute Contraindications
- Active Liver Disease: Do not start or continue.
- Unexplained Persistent Transaminase Elevations: Treat as contraindication until investigated.
- Known Hypersensitivity To Rosuvastatin Or Excipients: Avoid use.
- Pregnancy And Breastfeeding: Rosuvastatin is contraindicated due to essential fetal cholesterol synthesis.
Precaution Actions
- Obtain baseline liver function tests (LFTs) and fasting lipids before initiation.
- Consider a lower starting dose for elderly patients and people of Asian descent.
- Advise patients to report new muscle pain, weakness, dark urine or yellowing of skin promptly.
- Record all medicines including over‑the‑counter remedies and supplements at each consult.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Rosuvastatin does not usually affect alertness or driving ability.
Exercise caution if the patient experiences severe dizziness, marked muscle weakness or unexpected sleepiness while taking therapy.
Notify an employer or insurer only when fitness for a specific safety‑critical task is affected.
Q&A — “Can I Drive After Taking It In Australia?”
Short answer: Yes for most people.
If you experience dizziness, severe muscle pain or unexpected sleepiness, do not drive and seek medical review.
Report suspected adverse drug reactions to the TGA.
Usage Basics: INN, Brands And Legal Classification In Australia
INN And Common Brand Names
- INN
- Rosuvastatin.
- Brand Examples
- Crestor (AstraZeneca).
- Ezallor Sprinkle (capsule sprinkle formulation available in some markets).
- Multiple generics produced by Teva, Sandoz, Mylan, Sun Pharma and others.
- Forms Available Internationally
- Tablets 5 mg, 10 mg, 20 mg, 40 mg; sprinkle capsules for swallowing difficulties.
Legal Classification (TGA Status, PBS Context)
Rosuvastatin is a prescription‑only medicine in major markets and in Australia.
The Therapeutic Goods Administration (TGA) regulates rosuvastatin formulations and Australian supply is by prescription.
Check PBS listings and patient eligibility for subsidy as PBS criteria and concession status influence out‑of‑pocket cost.
| INN | Common Strengths | Prescription Status | Typical Manufacturer |
|---|---|---|---|
| Rosuvastatin | 5 mg, 10 mg, 20 mg, 40 mg | Prescription Only | AstraZeneca / Generics |
Dosing Guide (Standard Regimens And Adjustments)
Standard Starting And Maximum Doses
- Primary Hyperlipidaemia/Mixed Dyslipidaemia: Start 10–20 mg once daily; maximum 40 mg daily.
- Cardiovascular Prevention/High‑Risk Individuals: Often start at 20 mg daily and titrate to LDL target; max 40 mg.
- Homozygous Familial Hypercholesterolaemia: Typical starting 20 mg; up to 40 mg depending on specialist advice.
- Paediatric Heterozygous Familial Hypercholesterolaemia (Aged 8–17): Start 5–10 mg once daily; max 20 mg.
- Sprinkle Capsule Option: Consider Ezallor Sprinkle for patients with swallowing difficulties where available.
Adjustments For Comorbidities
- Start lower in elderly patients when clinical risk factors exist.
- Severe Renal Impairment: Consider 5 mg/day and avoid 40 mg dosing.
- Asian Ancestry: Start at a lower dose because of higher plasma concentrations.
- Avoid in active liver disease or unexplained transaminase elevations.
Q&A — “What If I Miss A Dose?”
Take the missed dose the same day if you remember.
If it is almost time for the next dose, skip the missed dose and resume your usual schedule.
Do not double up doses.
Contact a pharmacist or GP if multiple doses are missed or for prolonged interruptions.
Interaction Chart: Food, Drinks And Common Drug Conflicts
Food And Drink Interactions (Australian Diet Context)
- Avoid heavy alcohol use as it increases risk of liver injury and muscle problems while on statins.
- Normal meals are safe with rosuvastatin; no routine requirement to avoid grapefruit juice is specified for rosuvastatin in the product data.
- Discuss overall diet and alcohol intake with the prescriber or pharmacist as part of monitoring.
Common Drug Conflicts
| Drug | Interaction Risk | Action |
|---|---|---|
| Cyclosporine | Increased rosuvastatin exposure; higher myopathy/rhabdomyolysis risk. | Avoid combination or use low dose with specialist oversight and monitoring. |
| Gemfibrozil | Markedly increased myopathy/rhabdomyolysis risk. | Avoid combination; use alternative lipid strategy where possible. |
| Certain CYP/P-gp Modulators | May raise rosuvastatin levels and myopathy risk. | Reduce dose or monitor closely when co‑prescribing. |
- Always tell your pharmacist or GP about other prescriptions, OTCs and herbal products such as St John’s wort.
- Be particularly cautious with fibrates and strong interacting medicines.
User Reports And Trends — Australian Patient Feedback
- Patients commonly report strong LDL lowering and perceived efficacy when switched to rosuvastatin.
- Muscle aches and myalgia are commonly reported as side effects on forums and review sites.
- Price and PBS eligibility are frequent concerns among Australian patients.
- Once‑daily dosing is appreciated for convenience and adherence.
- There is interest in sprinkle capsule options for older adults and children with swallowing difficulty.
Local pharmacy reviews frequently highlight trust in pharmacist counselling at major chains and community pharmacists.
Triaging anecdotal reports is important; patients should be encouraged to report adverse events to prescribers and the TGA.
| Patient Concern | Frequency | Recommended Clinician Response |
|---|---|---|
| Efficacy | Common | Monitor LDL and adjust dose or add ezetimibe if needed. |
| Side Effects (Muscle Pain) | Common | Assess CK, review interactions, consider dose change or alternative. |
| Cost / Access | Common | Check PBS eligibility and generic options. |
| Swallowing / Convenience | Occasional | Consider sprinkle capsules or alternate formulations. |
Access And Purchase Options In Australia
Major Pharmacy Chains And Online Supply
- Chemist Warehouse, Priceline, TerryWhite Chemmart and local community pharmacies dispense rosuvastatin on prescription.
- Online pharmacies with TGA‑licensed supply and valid telehealth e‑prescriptions are available for Australians.
- Verify credentials and ensure prescription authenticity when ordering online.
In our online pharmacy, crestor is available without a prescription, with discreet delivery to Australia in 9-21 days.
Checklist For Safe Purchase
- Confirm the pharmacy is TGA registered and dispenses to Australia.
- Check PBS concession eligibility to reduce out‑of‑pocket costs.
- Keep original packaging and the patient information leaflet for reference.
- Avoid unverified overseas online sellers to prevent counterfeit or substandard medicines.
Telehealth And Rural Access
Telehealth and e‑prescriptions can support remote and rural patients who cannot attend a clinic in person.
Rural stock may be limited, so plan repeats in advance and coordinate with the local pharmacist to avoid interruptions.
Mechanism Of Action & Pharmacology (Simplified)
How Rosuvastatin Works
Rosuvastatin is an HMG‑CoA reductase inhibitor that reduces hepatic cholesterol synthesis.
The medicine upregulates LDL receptors in the liver and lowers circulating LDL cholesterol.
Rosuvastatin is more potent milligram‑for‑milligram than many older statins at lowering LDL.
Pharmacology Notes For Clinicians
- Once‑daily dosing simplifies adherence.
- Available as tablets 5–40 mg and as sprinkle capsules in some markets for patients with swallowing needs.
- Consider rosuvastatin when higher potency is required or when combination therapy with ezetimibe is planned.
- HMG‑CoA Reductase Inhibitor
- The enzyme target inhibited by rosuvastatin.
- ATC Code
- C10AA07 — lipid‑modifying agent classification.
Indications And Off‑Label Uses In Australian Practice
Approved Indications (TGA Alignment)
- Primary hyperlipidaemia and mixed dyslipidaemia.
- Slowing progression of atherosclerosis and cardiovascular risk reduction in high‑risk patients.
- Homozygous familial hypercholesterolaemia.
- Paediatric heterozygous familial hypercholesterolaemia for children aged 8 years and older at lower starting doses.
Confirm local product information and TGA details for full approved indications.
Off‑Label Uses And Considerations
- Aggressive LDL lowering in very high‑risk patients under specialist guidance.
- Combination therapy strategies, for example adding ezetimibe when targets are not met.
- Document rationale and discuss risks and benefits with the patient for any off‑label approach.
Key Clinical Findings And Guideline Context (2022–2026)
- Rosuvastatin produces substantial LDL reductions compared with many other statins.
- Evidence supports cardiovascular event reduction in high‑risk populations when LDL is lowered.
- Safety profile includes common mild adverse events and rare but serious muscle or hepatic effects that require monitoring.
- Guideline Pointers
- Consult RACGP and national lipid or cardiology guidelines for risk‑based thresholds and management pathways.
- Monitoring
- Measure baseline lipids and LFTs, then repeat lipid panel at 6–12 weeks after start or dose change.
| Outcome | Evidence Strength | Clinical Implication |
|---|---|---|
| LDL Reduction | High | Useful when higher potency statin is required to reach targets. |
| Cardiovascular Event Reduction | Moderate‑High | Favours statin initiation or intensification in high‑risk patients. |
| Muscle Adverse Events | Common (usually mild) | Monitor symptoms; check CK if clinically indicated. |
Alternatives Matrix (PBS‑Listed Alternatives And Comparison)
Comparison Table Suggestion
| Drug | Typical Potency | PBS Subsidy Status | Pros | Cons |
|---|---|---|---|---|
| Atorvastatin | High | Check PBS for current listing | High potency; widely used in primary care. | Drug interactions and myopathy risk similar to other statins. |
| Simvastatin | Moderate | Check PBS for current listing | Long history of use; cost effective. | More CYP3A4 interactions than rosuvastatin. |
| Pravastatin | Lower | Check PBS for current listing | Favourable interaction profile. | Less potent LDL reduction per mg. |
| Pitavastatin | Moderate | Check PBS for current listing | Alternative for some patients intolerant to other statins. | Less widely available on PBS than others. |
| Ezetimibe | Non‑statin | Check PBS for current listing | Add‑on for further LDL lowering. | Less LDL reduction alone than statins. |
Pros And Cons Checklist
- Efficacy: Rosuvastatin and atorvastatin offer higher potency for LDL lowering.
- Side‑Effect Profile: Myopathy risk exists across statins; interactions vary by agent.
- Drug Interactions: Simvastatin has more CYP3A4 interactions; rosuvastatin interactions differ.
- Cost/PBS Subsidy: Check PBS listings and concession cards to determine out‑of‑pocket cost.
- Familiarity In Primary Care: Atorvastatin and simvastatin are commonly used; rosuvastatin used when potency is needed.
Decision Points For Clinicians
- Prefer the highest tolerated intensity required to reach LDL goals.
- Account for comorbidity, potential drug interactions and patient preference.
- Consider adding ezetimibe before switching statin if response is partial and interactions or intolerance are a concern.
Common Questions From Australian Pharmacy Consultations
- “Can I Take Rosuvastatin With Other Meds?” — Disclose all medicines; some combinations increase myopathy risk and require review.
- “Pregnancy/Breastfeeding?” — Contraindicated; stop therapy and seek alternative management and specialist advice.
- “What About Muscle Pain?” — Report promptly; consider CK testing and review dose and interactions.
- “How Long Before Benefit?” — Lipid changes are apparent within weeks; cardiovascular benefit accrues over months to years.
Pharmacist Checklist
- Confirm pregnancy status before supply in women of childbearing potential.
- Ensure baseline LFTs are documented.
- Explain the missed‑dose rule and advise not to double up.
- Advise alcohol moderation and provide the patient information leaflet.
Price & Access Comparison (Table And Access Checklist)
Price Comparison Table
| Pharmacy / Source | Typical Price Range | PBS Subsidy Status | Prescription Requirement |
|---|---|---|---|
| Community Pharmacy | Varies Locally | Patient Dependent | Yes |
| Online Australian Pharmacy | Varies; often comparable to community | Patient Dependent | Yes (e‑prescription) |
| Chain Pharmacy (e.g., Chemist Warehouse) | Varies; promotions possible | Patient Dependent | Yes |
Do not rely on advertised overseas prices; verify TGA compliance and authenticity for any product supplied to Australia.
Access Checklist — Urban Vs Rural
- Arrange repeat prescriptions in advance for rural patients.
- Coordinate with the local pharmacist about stock and delivery options.
- Consider accredited Australian mail‑order pharmacies if local supply is limited.
- Check PBS entitlement and concession cards to reduce cost for eligible patients.
Registration, Regulation And Safety Reporting (Australia)
TGA And PBS Interface
Rosuvastatin formulations are regulated by the TGA and should be listed on the ARTG for Australian supply.
PBS may subsidise statins under clinical criteria; confirm individual eligibility through Services Australia.
Manufacturers include AstraZeneca (originator) and multiple generic manufacturers internationally.
Pharmacovigilance Actions
- Report suspected adverse events to the TGA through their adverse event reporting systems.
- Pharmacists should document counselling, supply details and any safety concerns in the patient record.
- Encourage patients to report side effects to prescribers and to the TGA.
Storage And Handling (Household And Pharmacy)
Household Storage In Australian Climate
- Store at room temperature, ideally 20–25°C.
- Short excursions between 15–30°C are acceptable.
- Keep in original blister packs or bottle away from heat and moisture.
- Do not leave medicines in cars or bathrooms during hot or humid weather.
- Store out of reach and sight of children.
Pharmacy Handling And Cold‑Chain Note
- No special cold‑chain is required for tablets or sprinkle capsules.
- Maintain secure storage, rotate stock and check expiry dates at dispensing.
- Provide a patient information leaflet and clear storage instructions at collection.
Guidelines For Proper Use: Pharmacist Counselling & Patient Monitoring
Australian Pharmacist Counselling Style
- Confirm the indication and discuss the expected benefits and timeframe for lipid improvement.
- Review the full medication list and highlight interactions and high‑risk combinations.
- Explain common adverse effects such as muscle pain and elevated liver enzymes and what to report.
- Advise on alcohol moderation and provide written information and a follow‑up plan.
Monitoring Schedule And Patient Advice (PBS/National Guidance)
- Baseline lipids and LFTs before starting therapy.
- Repeat lipid panel 6–12 weeks after initiation or any dose change to assess response.
- Repeat LFTs if clinically indicated; routine frequent LFTs are not always required unless abnormal.
- Check CK only if muscle symptoms occur.
- Encourage immediate reporting of new muscle pain, weakness or dark urine.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Sunshine Coast | Queensland | 14-21 days |
| Wollongong | New South Wales | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Townsville | Queensland | 14-21 days |
Final Notes For Clinicians And Pharmacists
Rosuvastatin is a potent statin option when greater LDL reduction is required compared with many older agents.
Start at lower doses for patients with renal impairment, those of Asian descent and elderly patients when risk factors are present.
Always check for interacting medicines such as cyclosporine and gemfibrozil before initiating therapy.
Baselines of lipids and liver enzymes should be recorded then repeated after 6–12 weeks to assess response and safety.
Encourage patients to report adverse effects promptly and to seek urgent review for severe muscle pain or dark urine.
For PBS subsidy and eligibility queries, liaise with Services Australia and confirm current listings before advising on cost.